Endostar included in CSCO Guidelines on the Diagnosis and Treatment

On April 22, 2018, the First Edition of 《Chinese Society of Clinical Oncology (CSCO) Guidelines on the Diagnosis and Treatment of Conventional Osteosarcoma (2018 Edition)》was formally released at the CSCO Guidelines Meeting, filling the gaps in the field in China.


Recombinant Human Endostatin (Endostar®), Simcere’s biological oncology drug is included in the first line recommendation of this guidelines to be combined with chemotherapy for pre-operative treatment of stage IIB/III Osteosarcoma.


Endostar®, originally indicated for Non-Small-Cell-Lung cancer,is shown in a prospective controlled clinical study to be able to significantly reduce the distant metastasis rate in Osteosarcoma patients, and prolong 5-year overall survival rates by 11% (86% V 75%,P=0.028) to as high as 85%.


The product is also formally listed in the National Health Insurance Catalogue since 2017.

Related News